E0714 selectively activates Kv7.2 channel subtype and showed potent antiepileptic effects without motor side effects in epilepsy models.
Does E0714 provide antiepileptic effects without motor coordination problems in classical epilepsy models?
E0714 is a highly selective Kv7.2 agonist that demonstrates antiepileptic efficacy in preclinical models without motor side effects, providing a framework for subtype-selective Kv7 drug design.
Subtype selectivity is critical in drug development, since off-target effects can restrict clinical application. Kv7.2 is a key target for treating neuronal hyperexcitability disorders. Nonselective activation of Kv7 channels can cause multisystem effects and increase therapeutic risk. Through a detailed analysis of Kv7 subtypes, we identified Kv7.2-specific residues to design a selective binding pocket. E0714 was then developed based on this pocket by virtual screening and compound modification. Electrophysiology assays demonstrated that E0714 potently activates Kv7.2 without significantly affecting Kv7.1, Kv7.3, Kv7.4, or Kv7.5. E0714 exhibited an excellent antiepileptic effect in classical epilepsy models without causing motor coordination problems. Mechanistic studies revealed that E0714 targets the Kv7.2-specific residues F112, Y118, and N289, which are responsible for the compound’s subtype-selective activation. These findings clarify the mechanism of action of E0714 and provide a framework for designing highly selective drugs against other Kv7 subtypes.
Qiao et al. (2026) studied this question. E0714 selectively activates Kv7.2 channel subtype and showed potent antiepileptic effects without motor side effects in epilepsy models.